- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: BI 6727 | BI-6727
Compound class: Synthetic organic
Comment: Volasertib is an ATP-competitive, investigational inhibitor of polo-like kinase 1 (PLK1). It is the second in a novel class of drugs called dihydropteridinone derivatives . This compound is represented on PubChem by CID 10461508. This CID varies slightly in its chiral specification from our ligand entry. Our structure was drawn from the image submitted to the WHO for the INN (note that the long chemical name provided for the INN registration is not sufficient to resolve absolute stereochemistry as depicted in the accompanying image). Some bioactivity may be linked to the trihydrochloride salt form.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
1. Barr FA, Silljé HH, Nigg EA. (2004)
Polo-like kinases and the orchestration of cell division.
Nat. Rev. Mol. Cell Biol., 5 (6): 429-40. [PMID:15173822]
2. Santamaria A, Neef R, Eberspächer U, Eis K, Husemann M, Mumberg D, Prechtl S, Schulze V, Siemeister G, Wortmann L et al.. (2007)
Use of the novel Plk1 inhibitor ZK-thiazolidinone to elucidate functions of Plk1 in early and late stages of mitosis.
Mol. Biol. Cell, 18 (10): 4024-36. [PMID:17671160]
3. Schöffski P. (2009)
Polo-like kinase (PLK) inhibitors in preclinical and early clinical development in oncology.
Oncologist, 14 (6): 559-70. [PMID:19474163]
4. Zhang Q, Xia Z, Mitten MJ, Lasko LM, Klinghofer V, Bouska J, Johnson EF, Penning TD, Luo Y, Giranda VL et al.. (2012)
Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors.
Bioorg. Med. Chem. Lett., 22 (24): 7615-22. [PMID:23103095]